Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse

Xenobiotica

Volumn 32, Issue 4, 2002, Pages 339-347

  Stinson, S F ^a   House, T ^a   Bramhall, C ^a   Saavedra, J E ^a   Keefer, L K ^a   Nims, R W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZENIUM DIOLATE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG STRUCTURE; FIRST PASS EFFECT; LIVER; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PLASMA;

ANIMALS; AZO COMPOUNDS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PYRROLIDINES;

ANIMALIA;

EID: 0036260242     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110102665     Document Type: Article

References (23)

1. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers
2. Boundary layer infusion of nitric oxide reduces early smooth muscle cell proliferation in the endarterectomized canine artery
3. Thromboresistant chemical sensors using combined nitric oxide release/ion sensing polymeric films
4. Donors of nitrogen oxides
5. Nitric oxide donors: A continuing opportunity in drug design
6. Design of nitric oxide-releasing drugs
7. 'NONOates' (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms
8. Theoretic aspects of pharmacokinetic drug interactions
9. Nitric oxide donors - Current trends in therapeutic applications
10. The liver-selective nitric oxide donor, V-PYRRO/NO, protects against d-galactosamine/endotoxin-induced hepatotoxicity in mice
11. The route of absorption of intraperitoneally administered compounds
12. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects
13. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release
14. Intraperitoneal and intraportal administration of droloxifene to the Sprague-Dawley rat: Assessing the first-pass effect
15. Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia
16. Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat
17. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage
18. V-PYRRO/NO: An hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion
19. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-a-induced apoptosis and toxicity in the liver
20. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor
21. - group